CN102413837B - 预防再激活的结核病tb疫苗 - Google Patents

预防再激活的结核病tb疫苗 Download PDF

Info

Publication number
CN102413837B
CN102413837B CN201080017717.7A CN201080017717A CN102413837B CN 102413837 B CN102413837 B CN 102413837B CN 201080017717 A CN201080017717 A CN 201080017717A CN 102413837 B CN102413837 B CN 102413837B
Authority
CN
China
Prior art keywords
vaccine
infection
tuberculosis
polypeptide
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080017717.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102413837A (zh
Inventor
J·迪特里希
彼得·安德森
卡里纳·温斯波·伦德贝里
特吕克·蒂·吉姆·坦·候昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Serum Institute
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Priority to CN201410141208.5A priority Critical patent/CN104107425B/zh
Publication of CN102413837A publication Critical patent/CN102413837A/zh
Application granted granted Critical
Publication of CN102413837B publication Critical patent/CN102413837B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201080017717.7A 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗 Active CN102413837B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410141208.5A CN104107425B (zh) 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24
DKPA200900539 2009-04-24
PCT/DK2010/000054 WO2010121618A1 (en) 2009-04-24 2010-04-23 A tuberculosis tb vaccine to prevent reactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410141208.5A Division CN104107425B (zh) 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗

Publications (2)

Publication Number Publication Date
CN102413837A CN102413837A (zh) 2012-04-11
CN102413837B true CN102413837B (zh) 2015-11-25

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080017717.7A Active CN102413837B (zh) 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗
CN201410141208.5A Active CN104107425B (zh) 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410141208.5A Active CN104107425B (zh) 2009-04-24 2010-04-23 预防再激活的结核病tb疫苗

Country Status (17)

Country Link
US (2) US9074001B2 (enExample)
EP (1) EP2421557B1 (enExample)
JP (2) JP5839361B2 (enExample)
KR (2) KR20120014176A (enExample)
CN (2) CN102413837B (enExample)
AU (1) AU2010238943B9 (enExample)
BR (1) BRPI1006452A2 (enExample)
CA (1) CA2759583C (enExample)
DK (1) DK2421557T3 (enExample)
ES (1) ES2714383T3 (enExample)
HK (1) HK1204549A1 (enExample)
IL (1) IL215591A (enExample)
MX (2) MX2011011186A (enExample)
PL (1) PL2421557T3 (enExample)
TR (1) TR201903223T4 (enExample)
WO (1) WO2010121618A1 (enExample)
ZA (1) ZA201108564B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
UA107330C2 (uk) * 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
WO2010010179A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
EP2315597B1 (en) 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
PL2528621T3 (pl) 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
PL2661253T3 (pl) 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
ES2670493T3 (es) 2012-01-12 2018-05-30 Archivel Farma, S.L. Vacuna de MTB-C contra respuestas alérgicas
CN104736555B (zh) * 2012-10-23 2019-06-21 国家血清研究所 结核分枝杆菌疫苗
AU2014232335C1 (en) 2013-03-15 2016-09-01 The Trustees Of The University Of Pennsylvania Synthetic immunogens for prophylaxis or treatment of tuberculosis
US10641770B2 (en) * 2013-12-16 2020-05-05 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
MX2020011298A (es) 2018-04-26 2021-01-29 Childrens Nat Medical Ct Composiciones de antígeno micobacteriano y métodos de uso.
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
KR20250082868A (ko) 2023-11-30 2025-06-09 서울대학교산학협력단 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用
CN120192426B (zh) * 2025-03-04 2025-11-11 江西澄实生物科技有限公司 一种预防沙门氏菌感染的疫苗及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104108A (zh) * 1994-04-15 1995-06-28 焦安国 一种治疗结核病的药物
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
ATE339436T1 (de) 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP1200466A2 (en) 1999-07-13 2002-05-02 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
CA2433236C (en) * 2001-01-08 2016-10-04 Isis Innovation Limited Assay to determine efficacy of treatment for m. tuberculosis infection
DE60236573D1 (de) * 2002-04-05 2010-07-15 Pasteur Institut Identifizierung der Virulenz-assoziierten Regionen RD1 und RD5, die die Entwicklung von verbesserten Impfstoffen mit M. bovis BCG und M. microti ermöglicht
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
NZ555907A (en) * 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
MX2007008182A (es) * 2005-01-05 2008-02-19 Isis Innovation Composiciones para inmunizar contra micobacteria.
PL2457926T3 (pl) 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
AU2006261445B2 (en) 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
RU2490024C2 (ru) * 2006-06-28 2013-08-20 Статенс Серум Инститьют Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
UA107330C2 (uk) 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1104108A (zh) * 1994-04-15 1995-06-28 焦安国 一种治疗结核病的药物

Also Published As

Publication number Publication date
JP5839361B2 (ja) 2016-01-06
AU2010238943A1 (en) 2011-11-03
JP6215260B2 (ja) 2017-10-18
IL215591A0 (en) 2011-12-29
MX2011011186A (es) 2012-02-13
HK1204549A1 (en) 2015-11-27
US9074001B2 (en) 2015-07-07
AU2010238943B9 (en) 2015-10-15
AU2010238943B2 (en) 2015-09-17
CA2759583C (en) 2020-06-16
HK1166018A1 (zh) 2012-10-19
US20150093407A1 (en) 2015-04-02
KR20120014176A (ko) 2012-02-16
IL215591A (en) 2016-03-31
ZA201108564B (en) 2018-11-28
CA2759583A1 (en) 2010-10-28
DK2421557T3 (en) 2019-03-25
CN102413837A (zh) 2012-04-11
BRPI1006452A2 (pt) 2016-12-27
KR20170072366A (ko) 2017-06-26
AU2010238943A9 (en) 2015-10-15
TR201903223T4 (tr) 2019-03-21
MX370744B (es) 2019-12-20
US10519202B2 (en) 2019-12-31
JP2015199771A (ja) 2015-11-12
CN104107425A (zh) 2014-10-22
EP2421557A1 (en) 2012-02-29
JP2012524733A (ja) 2012-10-18
ES2714383T3 (es) 2019-05-28
US20120039925A1 (en) 2012-02-16
CN104107425B (zh) 2018-07-17
WO2010121618A1 (en) 2010-10-28
PL2421557T3 (pl) 2019-07-31
EP2421557B1 (en) 2018-12-05
EP2421557A4 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
CN102413837B (zh) 预防再激活的结核病tb疫苗
EP1523331B1 (en) Therapeutic tb vaccine
JP5219808B2 (ja) 改良された結核ワクチン
AU2001250294A1 (en) Tuberculosis antigens and methods of use thereof
WO2005061534A2 (en) Improved tuberculosis vaccines
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
HK1166018B (en) A tuberculosis tb vaccine to prevent reactivation
AU2011203012A1 (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1124071B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase
HK1179855B (en) Tuberculosis vaccines comprising antigens expressed during the latent infection phase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Two thousand and three hundred Copenhagen, Denmark 5, Vijay Adler

Applicant after: Statens Seruminstitut

Address before: Copenhagen, Denmark

Applicant before: Statens Seruminstitut

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166018

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Copenhagen, Denmark 5, Vijay Adler

Patentee after: National Serum Institute

Address before: Copenhagen, Denmark 5, Vijay Adler

Patentee before: Statens Seruminstitut

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166018

Country of ref document: HK